Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

An experimental treatment appears to postpone Alzheimer's symptoms in some people genetically destined to get the disease at ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

A European regulatory committee rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially dangerous risks of brain bleeding and swelling.

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Tanto Kisunla como Leqembi son anticuerpos fabricados en laboratorio, administrados por vía intravenosa, que se dirigen a uno ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...

Biogen and Eisai's Leqembi (lecanemab), the other beta-amyloid-targeting Alzheimer's drug on the market in the US, carries a similar warning, though patients in clinical trials seemed to experience ...